Telavancin

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D. BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

FDA

  • Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
  • HAP and VAP caused by susceptible isolates of S. aureus.
    • It should be reserved for use when alternative agents are not suitable.

NON-FDA APPROVED USES

  • S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 2, 2018